Candel Therapeutics (CADL) Assets Average (2021 - 2025)

Candel Therapeutics has disclosed Assets Average across 5 years of filings, most recently posting $109.4 million for Q4 2025.

• Assets Average for Q4 2025 came in at $109.4 million, up 70.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $109.4 million (up 70.42% YoY), and the FY2025 annual result was $116.0 million, up 56.73% from the prior year.
• Assets Average came in at $109.4 million for Q4 2025 at Candel Therapeutics, up from $99.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $109.4 million in Q4 2025 to a low of $24.0 million in Q3 2024.
• The 5-year median for Assets Average is $76.9 million (2022), against an average of $73.3 million.
• Across the five-year window, Assets Average slumped 55.87% in 2024 and jumped 315.75% in 2025, its largest moves.
• Candel Therapeutics' Assets Average stood at $92.6 million in 2021, then dropped by 12.13% to $81.3 million in 2022, then sank by 43.91% to $45.6 million in 2023, then jumped by 40.68% to $64.2 million in 2024, then soared by 70.42% to $109.4 million in 2025.
• The last three Assets Average figures came in at $109.4 million (Q4 2025), $99.8 million (Q3 2025), and $100.9 million (Q2 2025), per Business Quant data.